Insider Trading Activity Aimmune Therapeutics, Inc. (NASDAQ:AIMT) – Insider Sold 3,283 shares of Stock

ME Staff
-
0

Insider Trading Activity For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)

Daniel C Md Adelman , Insider of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) reportedly Sold 3,283 shares of the company’s stock at an average price of 40 for a total transaction amount of $131,320.00 SEC Form

Insider Trading History For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)

  • On 3/29/2016 Longitude Capital Partners Ii,, Major Shareholder, bought 78,504 with an average share price of $13.87 per share and the total transaction amounting to $1,088,850.48.View SEC Filing
  • On 5/31/2016 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 240,000 with an average share price of $15.23 per share and the total transaction amounting to $3,655,200.00.View SEC Filing
  • On 9/8/2016 Mary M Rozenman, Insider, sold 30,000 with an average share price of $16.80 per share and the total transaction amounting to $504,000.00.View SEC Filing
  • On 10/5/2016 Mary M Rozenman, Insider, sold 25,000 with an average share price of $16.80 per share and the total transaction amounting to $420,000.00.View SEC Filing
  • On 11/4/2016 Mary M Rozenman, Insider, sold 24,096 with an average share price of $17.60 per share and the total transaction amounting to $424,089.60.View SEC Filing
  • On 3/21/2017 Warren L Desouza, CFO, sold 10,000 with an average share price of $22.95 per share and the total transaction amounting to $229,500.00.View SEC Filing
  • On 4/3/2017 Warren L Desouza, CFO, sold 15,000 with an average share price of $21.58 per share and the total transaction amounting to $323,700.00.View SEC Filing

    • Analyst Ratings History For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)

    • On 5/16/2016 Bank of America Reiterated Rating Buy
    • On 9/26/2016 JMP Securities Initiated Coverage of rating Outperform with a price target of $30.00
    • On 10/23/2017 Credit Suisse Group Boost Price Target of rating Outperform with a price target of $36.00 to $45.00
    • On 11/20/2017 Roth Capital Initiated Coverage of rating Buy to Buy with a price target of $60.00
    • On 12/1/2017 Wedbush Reiterated Rating Outperform with a price target of $70.00
    • On 12/5/2017 Piper Jaffray Companies Boost Price Target of rating Overweight with a price target of $38.00 to $60.00
    • On 12/12/2017 Cantor Fitzgerald Initiated Coverage of rating Overweight with a price target of $55.00

    Recent Trading Activity for Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
    Shares of Aimmune Therapeutics, Inc. closed the previous trading session at 37.82 down -0.96 2.48% with 38.88999938964844 shares trading hands.